Literature DB >> 9772874

Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia.

M Colombel1, F Vacherot, S G Diez, E Fontaine, R Buttyan, D Chopin.   

Abstract

OBJECTIVE: To determine whether benign prostatic hyperplasia (BPH) results from an imbalance between cell proliferation and apoptosis, and the extent to which the rates of these opposing processes are altered with the expression of the anti-death oncoprotein bcl-2.
MATERIALS AND METHODS: Ten prostate glands from normal men (mean age 43.7 years) were sampled according to McNeal's zonal anatomy, in addition to 30 prostate adenomas obtained from prostatectomy specimens from symptomatic patients (mean age 61.4 years). Tissue samples were fixed in formalin and embedded in paraffin. Proliferation and bcl-2 expression were assessed by immunostaining using Mib-1 and anti-bcl-2 antibodies, while apoptotic bodies were specifically stained using in situ nick translation. The percentage of positive cells was determined by optical microscopy.
RESULTS: In normal epithelium, the rates of proliferation and apoptosis were increased in the peripheral zone (Mib-1 1.7%, apoptotic bodies 3.3%) compared with the central (0.2% vs 1.4%) and transition (0.1% vs 1.8%) zones. Proliferation was significantly greater in BPH than in normal prostate tissue (3.7%), contrasting with a stable rate of apoptosis (1.4%). In the normal prostate, bcl-2 was expressed by glandular and basal cells in the peripheral zone. In the central zone, bcl-2 was overexpressed in basal cells and in most glandular cells of the intraluminal ridges. Bcl-2 expression in the transition zone was limited to dispersed basal cells. In BPH, bcl-2 was strongly expressed by basal cells in mature glandular formations and in most cells of young small nodules.
CONCLUSION: BPH may result from both an increase of proliferation within the basal compartment and a failure of apoptosis to counterbalance basal cell proliferation. Increased expression of bcl-2 may participate in this process by blocking apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9772874     DOI: 10.1046/j.1464-410x.1998.00752.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  17 in total

1.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  Sca-1 expression identifies stem cells in the proximal region of prostatic ducts with high capacity to reconstitute prostatic tissue.

Authors:  Patricia E Burger; Xiaozhong Xiong; Sandra Coetzee; Sarah N Salm; David Moscatelli; Ken Goto; E Lynette Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-17       Impact factor: 11.205

Review 3.  Chemokines and BPH/LUTS.

Authors:  Jill A Macoska
Journal:  Differentiation       Date:  2011-05-19       Impact factor: 3.880

4.  BCL-2 and BCL-XL expression are down-regulated in benign prostate hyperplasia nodules and not affected by finasteride and/or celecoxib.

Authors:  Feng Li; Laura E Pascal; Jianhua Zhou; Yibin Zhou; Ke Wang; Anil V Parwani; Rajiv Dhir; Peng Guo; Dalin He; Joel B Nelson; Zhou Wang
Journal:  Am J Clin Exp Urol       Date:  2018-02-05

5.  Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms.

Authors:  Xing Wei; Li Zhang; Zhicheng Zhou; Oh-Joon Kwon; Yiqun Zhang; Hoang Nguyen; Ruth Dumpit; Lawrence True; Peter Nelson; Baijun Dong; Wei Xue; Walter Birchmeier; Makoto M Taketo; Feng Xu; Chad J Creighton; Michael M Ittmann; Li Xin
Journal:  Cell Stem Cell       Date:  2019-04-11       Impact factor: 24.633

6.  Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.

Authors:  Tomoe Fujita; Yoshiaki Matsumoto; Toshimi Kimura; Shinichi Yokota; Mika Sawada; Masataka Majima; Yoshio Ohtani; Yuji Kumagai
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

7.  [Expression of corticotropin releasing factor receptor 2 (CRFR2) in the human prostate. A new potential target for medical therapy of benign prostatic hyperplasia].

Authors:  H Tezval; A S Merseburger; M Seidler; J Serth; M A Kuczyk; M Oelke
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 8.  An introduction to acinar pressures in BPH and prostate cancer.

Authors:  Panikar Wadhera
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

9.  Differential response to zinc-induced apoptosis in benign prostate hyperplasia and prostate cancer cells.

Authors:  Michelle Yan; Karin Hardin; Emily Ho
Journal:  J Nutr Biochem       Date:  2009-07-02       Impact factor: 6.048

Review 10.  Pharmacological effects of saw palmetto extract in the lower urinary tract.

Authors:  Mayumi Suzuki; Yoshihiko Ito; Tomomi Fujino; Masayuki Abe; Keizo Umegaki; Satomi Onoue; Hiroshi Noguchi; Shizuo Yamada
Journal:  Acta Pharmacol Sin       Date:  2009-03       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.